Higher dose may stall prostate cancer when standard fails
NCT ID NCT03458247
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 39 times
Summary
This study looked at men with advanced prostate cancer that was no longer controlled by standard hormone therapy. Researchers tested whether increasing the dose of the drug abiraterone could stop the cancer from growing. 94 men participated, and the goal was to see if the higher dose helped keep the disease stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Medical Oncology, Cochin Hospital
Paris, Paris, 75014, France
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.